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Simple Summary: 3D cell cultures are a qualitative improvement in cancer research because these
models preserve cancer physiological characteristics better than traditional bi-dimensional cultures.
Moreover, they facilitate the study of complex 3D interactions using extracellular matrices and
the co-culture of different cell types. In this manner, the cells can contact themselves in a fully
physiological but also controlled arrangement. In the context of tumor interactions, extracellular
vesicles are essential in number of key aspects in oncology: as major interactors with extracellular
matrix, as cell-to-cell messengers, as carriers of diagnostic-valuable biomarkers, and as target-specific
treatment-deliver agents. The present article aims to discuss the findings achieved using 3D culture
models in oncology. We further review the involvement of extracellular vesicles in the pathogenesis
of cancer as well as their potential use in diagnostics and therapeutics.
Abstract: The improvement of culturing techniques to model the environment and physiological
conditions surrounding tumors has also been applied to the study of extracellular vesicles (EVs)
in cancer research. EVs role is not only limited to cell-to-cell communication in tumor physiology,
they are also a promising source of biomarkers, and a tool to deliver drugs and induce antitumoral
activity. In the present review, we have addressed the improvements achieved by using 3D culture
models to evaluate the role of EVs in tumor progression and the potential applications of EVs in
diagnostics and therapeutics. The most employed assays are gel-based spheroids, often utilized to
examine the cell invasion rate and angiogenesis markers upon EVs treatment. To study EVs as drug
carriers, a more complex multicellular cultures and organoids from cancer stem cell populations
have been developed. Such strategies provide a closer response to in vivo physiology observed
responses. They are also the best models to understand the complex interactions between different
populations of cells and the extracellular matrix, in which tumor-derived EVs modify epithelial or
mesenchymal cells to become protumor agents. Finally, the growth of cells in 3D bioreactor-like
systems is appointed as the best approach to industrial EVs production, a necessary step toward
clinical translation of EVs-based therapy.
Keywords: 3D culture; extracellular vesicles; tumoral cells; cancer; therapy
1. Introduction
In recent years, the number of scientific groups dedicated to the study of extracellular
vesicles has grown notably, and with it the amount of published information describing
extracellular vesicles (EVs) physiology. Released by all types of cells, they are an important
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tool to study cell’s biology, and to look for biomarkers. Cancer research is one of the main
fields that can benefit of the study of EVs associated to tumors. In fact, the vesicle-mediated
cell-to-cell crosstalk seems to be important in every step of cancer progression [1]. In
parallel, the study of cancer biology had evolved itself along the last years towards culture
models that reflect the biological complexity of tumoral cells and their interactions with
the extracellular matrix. The reason is that the traditional bidimensional (2D) cultures
differ from tridimensional (3D) cultures in their morphological characteristics, proliferation
rate and degree of differentiation, the level of cell-to-cell interaction and cell-to-matrix,
as well as their resistance to drugs [2,3]. However, the application of complex culture
models to unravel the role of EVs in cancer research has not been yet popularized among
EVs research, given the difficulties that this type of cultures presents, both technically
and in terms of cost. Nevertheless, several studies have highlighted the importance of 3D
cultures in the study of EVs in cancer research [4–6]. In this article, we aim to emphasize
the contribution of those studies as a fundamental path to understand the involvement of
EVs in cancer physiology and to pinpoint possible applications to the clinical oncology. To
help to understand the background of this review, we are providing a short introduction to
the different roles that EVs play in cancer and cancer therapy, and a brief description of the
different 3D cultures employed to study tumoral cells. Afterwards, the review summarizes
different studies that employ 3D culture systems to elucidate the role of EVs in cancer
biology, diagnosis and therapy.
2. The 3D Cultures as a Physiological Model of Tumoral Cells
For many years, in vitro models were based on 2D monolayers of immortalized human
cancer-derived cell lines. The popularization of 3D culturing has come with the observation
that this type of cell cultures often retain heterogeneity. This feature allows the study of
tumor evolution. Moreover, 3D cultures offer advantages over conventional monolayered
cell cultures including preservation of the topology and cell-to-matrix interactions [7,8].
On the other hand, the application of 3D cultures is also challenging, given the difficulties
to stabilize the cultures, and the requirement of specific material to perform the culture. In
Table 1, we present a comparative between 2D and 3D cultures characteristics. In spite of
the difficulties, 3D cultures become a great model to study the interplay between cancer
and non-cancer cells in order to unveil biological mechanisms involved in cancers initiation
and progression [9]. Spheroids are probably the type of 3D culture most commonly used.
Spheroid formation methodologies can be divided into two categories: scaffold-based
models, either incorporating materials which are components of the matrix (collagen,
fibronectin, agarose, laminin, and gelatin) [10], or synthetic materials that provide cell
support [11], and scaffold-free models that comprise non-adherent and in suspension cells,
which are forced to aggregate and form spheroids [12].
Table 1. Main advantages and limitations of the different cellular models in cancer research [13,14].
Model Advantages Limitations
2D Monolayers
Easy and cost effective
Large amount of data available
Reproducible cultures, easy to work for downstream
applications and imaging
Reduced cell-to-cell interactions
Different sensitivity to drugs
Loss of biological characteristics over time
Gel based 3D Cultures
Cell–ECM interactions
Possible to incorporate different factors in the gel,
extending release over time
Uniform spheroids/organoids
Difficult to dispense cells
Change of growth media could be irregular
Difficult to retrieve cells and downstream analysis
Low-attachment plates
Simpler and cheaper when compared to gel
based systems
Long-term culture




Control of fluid rates
Convenient for multicellular cultures controlling
cell locations
Expensive commercial devices or not
well-characterized “in house” build devices
Fluidic problems related to bubbles and clogging
Cancers 2021, 13, 307 3 of 16
One of the first applications of 3D cultures was the study of tumorigenesis. Typically,
the cells are cultured in a mouse sarcoma-derived gel (i.e., Matrigel®). Other alternatives ex-
ist, such human leiomyoma discs and their matrix (Myogel). This has been commercialized
for in vitro assays such IncuCyte®, spheroid and sandwich assays [15].
3D culture models grown in vitro from cancer stem directly or from primary tissues
are a more evolved form of organoids [16]. The latter option has an attractive potential for
personalized medicine. For instance, when comparing organoids derived from primary
colorectal tumors and metastatic lesions isolated from the same patients, it has been
observed that they share common mutations. This implies that the driver alterations
preceded metastatic dissemination [17]. Organoids display greater number of features
and functions of their original organs, such architecture and gene expression, reason why
they have a prospective potential for the cancer research. The combination of organoids
with the co-culture of multiple cells can mimic the tumor immune microenvironment,
including key features like immune check point [18]. Organoids derived from different
mouse or human tumors have now been widely adopted to investigate different types of
cancer, for example. colorectal cancer [19]. Moreover, by culturing organoids in the proper
media conditions, they could serve as a model of the three most common subtypes of
liver cancer: hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular
cholangiocarcinoma [20]. Several other models such as prostate, brain or kidney organoids
have been stablished and largely reviewed in [21].
In addition to organoids, other kinds of 3D cultures have been developed. 3D bioprint-
ing can be defined as a layer-by-layer deposition of biomaterial, such as tissue spheroids,
cell pellets, microcarriers, decellularized extracellular matrix, and cell-laden hydrogels, in
a well-defined structure to generate viable 3D cultures. In the last decade, the bioprinting
technologies have undergone remarkable advancements [22]. Current trends utilizing scaf-
fold technologies aim at capturing more of the micro-environmental cues than other model
systems [23,24]. The scaffolds may act as a surrogate for the missing ECM, representing the
available space of tumor tissue, providing the physical support for cell growth, adhesion,
and proliferation, and causing the cells to form an appropriate spatial distribution and
cell-cell or cell-ECM interaction [2].
A wide range of techniques are used in generating different scaffolds, including
solvent casting/particulate leaching, freeze-drying, phase inversion, electrospinning, stere-
olithography, selective laser sintering, shape deposition manufacturing, 3D printing, robotic
microassembly, and fused deposition modeling [25]. Among these techniques, freeze dry-
ing, phase inversion, and fiber electrospinning are used most of the times. Commonly
materials used for tumor cells 3D culture are a laminin-rich basement membrane extract
gelatin (for instance Matrigel, Myogel or Cultrex BME) [26], silk fibroin proteins [27],
hyaluronic acid [28], collagen [29], or decellularized material [30,31]. Greater understand-
ings of tumor microenvironment have identified ECM to play critical roles in orchestrating
drug resistance, disease progression and tumor metastasis [32]. Two independent articles
have revealed that lack of ECM during 3D culture could not elicit pathological pheno-
types observed in vivo, such as maintaining cancer-associated fibroblasts behaviors [33]
or stromal barriers [34]. Scaffold based 3D cell culture, using a biological basement mem-
brane, captures many aspects of the spatial cues (cell-to-cell communication, cell-to-matrix
adhesion, and physical characteristics) and provides a unique compromise between com-
plexity and practicality [35]. The choice of a biological scaffold is not simply to deliver
an anchorage site for cells but also to provide a complex structure enabling communi-
cation linked to cell behavior and function [36]. The formation of 3D structures within
the culture also reproduces aspects of the nutrient and oxygen gradients found across
in vivo tumors. It should be considered that those 3D scaffolds can be used not only to
simulate the microenvironment but alto to assess drug research. Recently publications
have showed the ability of decellularized ECM materials to encapsulate and controlled
delivery of different drugs such as dexamethasone [37] or doxorubicin [38]. So, 3D scaffold
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can have drug-carrier functions in therapeutic applications related to testing drugs and in
predicting treatment efficacies.
In this review, we will find examples of the different 3D strategies employed to
study the different roles of extracellular vesicles in cancer, and which models are the most
employed to solve each question regarding the role of EVs in tumorigenicity processes
(Figure 1).
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3. Extracellular Vesicles in Cancer Research
Since the first descriptions of EVs and their different types, it has been reported that
tumoral cells secrete vesicles. These vesicles participate in the cellular cross-talk with the
cellular matrix [39] and cancer cells are rather effective in vesicular-mediated intercellular
transfer [40]. Actually, this transfer is a requirement of tumoral cells to stablish a connec-
tion with the surrounding matrix and to actively regulate processes involved in cancer
progression and autocrine/paracrine oncogenesis. Indeed, EVs play an important role in
reprogramming stromal cells, modulating the immune system, and promoting angiogene-
sis (reviewed in [41]). Moreover, the dependency of tumors on vesicular communication
also concerns the preparation of an extracellular niche for metastasis [42–44]. For more
detailed reviews about the implications of EVs in tumor biology and progression there are
very interesting reviews published along the last years [5,45,46], and there are also specific
publications related to prostate cancer EVs [6,8].
Tumor communication with targeted cells has a tight reliance on EVs. For this reason,
many opportunities for diagnostic and treatment appeared with the analysis and the
manipulation of EVs. It is well-known that most malignancies are associated with an
increase of circulating EVs. Moreover, it has been described that in different tumor models
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exist a correlation between tumor volumes and the concentration of circulating EVs in
blood [47]. These EVs carry a cargo with precious information about the tumor, and they
have become the substrate for biomarker digging in all types of malignancies [48–50]
including prostate cancer [51–53].
In parallel, many studies have focused on how circulating EVs are being captured by
tumoral cells, and how to increase the specificity of the capture of EVs by tumoral cells
using different strategies. An interesting line of research studies EV membrane decoration
with proteins. For example, LAMP2b protein has been successfully fused to ligands specific
for brain, angiogenic endothelium, or IL3 receptors on myeloid leukemia cells to direct EVs
specifically toward the selected tissue [54–56]. Other considerations, such as biodistribution,
permeability of tumoral cells, and ability to deliver the cargo shall be taken in account and
have been largely reviewed in [57].
All these examples unveil the need to deep into the understanding of the three
key aspects of cancer research: pathogenesis, diagnosis, and therapy. Below, we will be
described how 3D models have contributed to gain knowledge in those topics, and what
are the most interesting results obtained so far. For clarity, we talk about EVs even if
the original work refers to as exosomes; in most of those articles, the isolation methods
employed actually enriched the preparation in small vesicles, but not necessary in vesicles
originated from the endocytic pathway.
4. Production of EVs in 3D Cultures
As we mentioned previously, 3D culturing allows cells to grow in a physiological
topology, and organoids and spheroids still release EVs. More importantly, the EVs
produced are functional; EVs released by pancreatic cancer organoids can activate p38
MAPK and induce the expression of F-box protein 32 and UBR2 in myotubes [58]. When
compared to 2D conformations, 3D cultures show an increase in EVs release in the case
of colorectal cancer stem cells [59]. For colon cancer organoids, the presence of APC
mutations that activate WNT pathway enhanced the EVs release in Matrigel-based cultures.
This release was probably also favored by the presence of collagen (a component of the
extracellular matrix), since it is part of this type of gel [60]. Moreover, another plausible
explanation is that the release of EVs in 3D cultures may be partially driven by the higher
expression of transporters. The expression of the ATP-binding cassette transporter G1, a
cholesterol lipid efflux pump, was reported to be highly expressed in tumoroids of colon
adenocarcinoma cells with enhanced stemness. Likewise, the silencing of this transporter
blocks the release of EVs and increases the accumulation of intracellular vesicles [61].
Interestingly, cell architecture can be manipulated by applying different collagen
concentrations and adding components that are found naturally in the dermis such as
fibronectin. Breast cancer cells cultured in 3D following this approach experienced morpho-
logical alterations [62]. Moreover, these changes are translated into differences in the cargo
of secreted EVs population [62]. Remarkably, there is evidence that 3D culturing presents
different gene expression signatures due to the more physiological nanoenvironment of
this arrangement. For instance, prostate-derived adenocarcinoma cells (PC-3 and DU145)
form large and slowly growing organoids that express multiple stem cell markers, neu-
roendocrine markers and intercellular adhesion molecules likely to occur in vivo as well.
Importantly, 3D cultures promoted the secretion of HSP90 and EpCAM loaded EVs, which
are markers of cancer stem cells phenotype [63]. Another example of the physiological
environment effect has been observed in cervical cancer 3D cultures. In this case, the EVs
were loaded with a small RNA profile comparable (~96% similarity) to in vivo circulating
plasma-derived EVs from cervical cancer patients [64].
Moreover, tridimensional architecture allows a better cell orientation and asymmetry.
It implies that different populations of EVs loaded with different markers and cargo
proteins are released from apical and basal sides of the cells. As an example, organoids
derived from colon carcinoma cell line LIM1863 release two types of EVs. Apical EVs are
characterized by the presence of EpCAM, and the exclusive identification of the trafficking
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molecules CD63, mucin 13, and the apical intestinal enzyme sucrase isomaltase, but also an
increase in the expression of dipeptidyl peptidase IV and the apically-restricted pentaspan
membrane glycoprotein prominin 1 [65]. In contrast, EVs containing the colon epithelial
cell-specific A33 marker were enriched with basolateral trafficking molecules such as early
endosome antigen 1, the golgi membrane protein ADP-ribosylation factor, and clathrin.
These observations are consistent with EpCAM- and A33-EVs being released from the
apical and basolateral surfaces of colon carcinoma cells respectively [65].
One of the most important outcomes of the different alterations described here is that
cancer cells have a wide range of responses to their environment. In cancer cells response
to drugs, a higher release of EVs after chemotherapy treatments has been reported [66].
Interestingly, this observation has been useful to stablish a discovery pipeline of secreted
biomarkers in the media of organoid cultures and to identify new protein markers as a
response to chemotherapy [66].
Due to the lack of an established biomanufacturing platform for EVs, which is a
limitation for clinical translation, one of the most interesting applications of 3D cultures
is the large scale and standardizable production of EVs. A simple approach is the use of
bioreactor flasks since they increase the production of EVs released by tumoral cells [67].
A more interesting application is to use cell cultures in microfluidic platforms. These
automated devices can produce therapeutic exosomes, which could also be engineered,
and harvest them in real-time from the on-chip cultures. For instance, this type of tool
has been used in leukocytes isolated from human blood [68]. Alternatively, a 3D-printed
scaffold-perfusion bioreactor system has been employed to assess the effect of dynamic
cultures on the production of EVs from endothelial cells. With this approach the cells were
able to maintain their functionality (i.e., pro-vascularization bioactivity or pro-angiogenic
gene expression) [69].
5. Modelling the Antitumoral Effect of EVs in 3D Cultures
As we mentioned in the previous section, the arrangement of cells in tridimensional
conformations often suppose a better physiological model of drug therapy. This is also an
advantage to study the application of EVs as potential therapeutical assets against tumoral
cells. Up to date, multiple strategies have been designed to increase the antitumoral effect
of EVs (Figure 2). According to the literature, most of the 3D culture systems employed
to reveal the antitumoral effect of EVs are spheroids or organoids formed with tumor-
derived cell lines. Indeed, tumor spheroids are the most common models for testing drug
effectivity [70]. Notably, 3D cultures with a single type of cells are likely to exhibit different
drug responses than those composed of heterogenous populations of cells [70].
The spontaneous effect of normal cell-derived EVs has been investigated to use them
as natural antitumoral agents. For example, glia-derived EVs have shown an antitumoral
effect in spheroids of glioma cells by reducing the invasion capacity of the tumor over
time [71]. Another example are EVs derived from mesenchymal stroma cells (MSCs)
that can inhibit angiogenesis and maintain vascular homeostasis in activated endothelial
cells [72]. However, most of the publications focus on the possibility of loading EVs with
antitumoral drugs and biomolecules such amino acids, lipoproteins, or nucleic acids. The
antitumoral effect of EVs loaded with a specific miRNA (miR-497) has been assayed in
a microfluidic device containing a mixture of cells. These types of devices are useful in
combination with an extracellular matrix since it allows the study of migration in response
to a factor controlled by microfluidic channels [73]. In this case, the cells employed were
the non-small cell lung cancer cell line A549 cultured together with human umbilical vein
endothelial cells (HUVEC). In these conditions, the tube formation of endothelial cells
was inhibited and the migration of the tumor decreased dramatically compared to the
control [74]. To avoid limitation of the cocultures associated to cell separation after analysis,
both types of cells were separated in the microfluidic devices by Matrigel component. This
is a very interesting example of using 3D culturing to mimic the physiological complexity
of tumors.
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The efforts for loading EVs with antitumoral drugs are well documented in the liter-
ature. The importance of EVs as antitumoral agents lays upon the tumor avidity for vesi-
cles. Many approaches consist in loading the EVs with a chemotherapeutic agent. Alt-
hough still very inefficient, there are different strategies; the simplest methods consist in 
incubating the drugs with purified EVs [75], and an alternative is to treat parental cells 
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on the surface of the EVs allow a targeted loading of the drug (reviewed in [76]). For in-
stance, EVs obtained from endometrial cells have been loaded with atorvastatin and can 
induce significant apoptotic effects and inhibit the growth of glioblastoma spheroids [77]. 
Moreover, endothelial cell-derived EVs loaded with meta-tetra(hydroxyphenyl)chlorine 
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efforts for loading EVs with antitumoral drugs are well documented in the lit-
erature. The import nce of EVs as ntitumor l agents lay upon t e tumor avidity for
vesicles. Many approaches consist in loadi t EVs with chemotherapeutic agent.
Although still very ineffici nt, there are different strat gies; the simplest methods consis
in incubating the drugs with purified EV [75], and an alternative s to treat parent
with the drug that w uld be released by EVs. In a more soph sticated way, a mod fic tion
on the su face of the EVs allow a targeted loa ing of the drug ( eviewed in [76]). For
instance, EVs obtained fr m ndometrial cells have been loaded with atorvastatin and can
induce s gnificant ap ptotic effects and inhibit the growth of glioblastoma sphero ds [77].
More ver, endotheli l cell-derived EVs loaded ith meta-tetra(hyd oxyphenyl)chlorine
can penetrate up to 100 µm in multicellular tumor organoids. Con equently, these EVs
increased photodynami activity, which translat s into higher rates of cell ortality [78].
This is a promising result that shows an improvement in the pe etration capability com-
pared to liposomes, and he ce in the vectorization molecules capabilities. Furthermore, the
production of EVs from patient-derived cells is an interesting strategy to overcome many
of the problems associated with bioreagent-based therapy. The treatment of melanoma
spheroids with macrophage-derived EVs loaded with acridine orange has maintained the
delivery of this drug for longer time in comparison to the treatment with free acridine
orange [79].
A more sophisticated approach to design antitumoral EVs is their decoration with
molecules that promote the interaction between cells and vesicles. This strategy has
described an increase of the avidity and specificity of cells to uptake the decorated EVs. For
instance, HepG2 cells and human primary liver cancer-derived organoids accumulate more
efficiently EVs that have been decorated with tetrahedral DNA nanostructures conjugated
with DNA aptamer [80]. These EVs can effectively deliver an engineered cargo, which
consists of CRISPR-Cas9 RNA-guided endonucleases, aiming to silence the expression of
the protein Wnt-10b. In fact, these EVs inhibited the growth of tumoral cells in vitro [80].
Another strategy was to decorate methotrexate-loaded EVs with Lys-Leu-Ala bound to
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low-density lipoprotein peptides. The functionalization of the methotrexate-loaded EVs
increased the uptake by human primary glioma cell line U87 growing into 3D glioma
spheroids and increased the cell mortality rate [81]. Although the use of EVs as carrier of
antitumoral molecules is very promising, there are still several limitations. For example,
this type of EVs-based drug delivery approach needs accurate isolation methods for those
EVs subpopulation that display favorable tropism and the understanding of EVs transport
properties is still scarce. In addition, scalable manufacturing remains a major hurdle for
clinical translation [82]. A very detailed revision of ongoing clinical trials regarding the use
of EVs can be found in [83].
An attempt to overcome some of these problems is the use of EVs mimetics. One
of the first solutions to generate “on demand” EVs was to obtain them by shearing cells
through a sequential filtering. When loaded with doxorubicin, these EVs mimetics were
more effective in targeting ovarian cancer cells in 3D cultures than free doxorubicin. In
addition, they showed a higher encapsulation efficiency and drug release over time in
comparison to naturally released EVs [84]. Spheroids derived from cancer stem cell have
been targeted with tumor-cell-exocytosed nanoparticles made of porous silicon. These
synthetic particles loaded with doxorubicin are fed to tumoral cells, which release the
nanoparticles with the doxorubicin inside of EVs. This approach greatly improves drug
performance over hepatocarcinoma spheroids in comparison to free doxorubicin or the
direct use of synthetic particles (Figure 2) [85].
6. EVs-Mediated Crosstalk between the Tumor and Cellular Matrix
6.1. Tumoral Cells Modify Surroundings Cells through EVs
EVs are released by malignant cells and can further influence the cellular components
of the matrix. There are different models employed to study that effect, which vary
from low to high complexity. Synthetic gel cultures are the most employed models to
study the invasion or tubule formation in cultures with a single type of cell models. A
classic example of these type of models is represented by the treatment of HUVEC cells
cultured on Matrigel with EVs derived from chronic myelogenous leukemia. It causes the
reorganization of HUVEC cells into tubes [86] but also, the movement of EVs within and
between nanotubular structures further connecting the remodeled endothelial cells [87].
In addition, the effect of renal cancer cell-derived EVs, which induce VEGF expression in
HUVEC cells has also been described [88].
Regarding the tumor-matrix crosstalk, MSCs probably are the most interesting players
due to their response to EVs treatment in bioengineered 3D microenvironments. EVs
derived from MDA-MB-231 (metastatic breast cancer cell line) have shown to convert
MSCs into tumor-activated MSCs. This results in an immunomodulatory phenotype that
was particularly prominent in response to bone-tropic cancer cells. In contrast, MCF7
(considered a non-metastatic breast cancer cell line) -derived EVs failed to generate this
phenotype in the MSCs culture [89]. It has also been reported that colorectal EVs induce
alterations in colonic MSCs morphology and increase MSCs proliferation, migration, and
invasion. Colorectal EVs also provoke a higher ability to form spheroids, and an impact on
the metabolic respiration by the acidification of the extracellular environment associated
with a plasma membrane redistribution of vacuolar H+-ATPase. They also increase the
expression of the carcinoembryonic antigen. These modifications suggest that colorectal
cell-derived EVs are able to activate MSCs to favor tumor growth and malignant progres-
sion [90]. Likewise, the treatment of ovarian cancer spheroids with cisplatin showed a
release of EVs that can alter MSC cells. These MSCs displayed an increase in the migration
pattern and secreted more amount of interleukin-6 (IL-6), interleukin-8 (IL-8), and VEGFA.
Moreover, bone marrow MSCs induce angiogenesis in endothelial cells and the migration
of low-invasive ovarian cancer cells upon contact with EVs [91].
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The effect of prostate cancer EVs dominates a new program of MSC differentiation
that impairs both the classical adipogenic differentiation and the skewing differentiation
towards alpha-smooth muscle actin (αSMA) positive myofibroblastic cells (Figure 3). The
differentiated MSC performed pro-angiogenic functions and enhanced the tumor pro-
liferation and invasivity in a 3D co-culture model. In this case, the differentiation was
dependent on TGFβ containing EVs. Remarkably, a comparable dose of soluble TGFβ
could not generate the same phenotype [92]. Tumor-derived EVs can target fibroblasts
directly. Moreover, early-stage primary colorectal adenocarcinoma cells have shown to be
unable to invade Matrigel matrix themselves. Alternatively, they secrete EVs to reprogram
normal fibroblasts and acquire a de novo capacity to invade first the matrix and thence,
the adenocarcinoma cells. It is worth to mention that EVs upregulate fibroblast proteins
implicated in focal adhesion, regulators of actin cytoskeleton and signaling pathways
important in pro-invasive remodeling of extracellular matrix [93]. In addition, epithelial
cells can be transformed by tumoral EVs; a recent study described how human peritoneal
mesothelial cells treated with epithelial ovary cancer-derived EVs accumulate miR-99a-5p.
The presence of miR-99a-5p drives the invasion in a 3D Matrigel culture model due to a
higher expression levels of fibronectin and vitronectin [94].
Multiple cellular models are more complex than single cell cultures and are interesting
structures to mimic tumor complexity. The development of multicellular lung organoids
mimicking the lung microenvironment with air sac-like structures and lung surfactant
proteins has shown that pretreating the cells with tumor exosomes triggered cancer cell
colonization. Notably, the sensitivity to drug therapy described in this multicellular model
is closer to in vivo observations rather than the sensitivity obtained with 2D or single cell
3D cultures [70]. The other major advantage of multicellular cultures is that they allow the
study of different interactions simultaneously. However, it is worth to remark that these
desirable characteristics can only be achieved through an extensive experimental testing,
and such characterization is challenging, since synthetic multi-population systems are
among the most complex systems described to date [95]. A successful example is the design
of a microfluidic device with multiple cells that mimics the tumor microenvironment in situ,
including extracellular matrix (ECM), interstitial flow and environmental EVs. Such device
has been employed to study the endothelial-mesenchymal transition (EMT). The number of
cancer-associated fibroblasts (CAFs) differentiated from HUVECs increased upon treatment
with melanoma-derived EVs, hence promoting EMT. The negative pro-tumorogenic effect
of cancer-derived EVs over HUVEC cells could be intensified by the enrichment of miR-
221-3p containing EVs [96]. In cervical squamous carcinoma cells derived EVs, vesicular
miR-221-3p promoted angiogenesis in Matrigel tube formation assay, but also an increase
in spheroid sprouting and migration, and induced a faster wound healing. Moreover,
cancer stem carcinoma cell-derived EVs transport miR-221-3p from cancer cells to vessel
endothelial cells and promote angiogenesis by downregulating the protein THBS2 [96].
On another hand, the transformation from fibroblast to myofibroblast can be impaired
by depleting RAB35. The phenotype of the remaining EVs population is insufficient to
drive the fibroblast to myofibroblast differentiation, showing attenuated motile behaviors
in 3D in vitro models [97]. In contrast, MSCs derived EVs suppress EMT, maintain vascular
homeostasis, and ultimately lead to the recovery of CAFs back to endothelial cells [72].
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motility, invasiveness and stemness of primary tumor cells SW480 [99]. A study with
pancreatic ductal adenocarcinoma cells (PDAC) have demonstrated that the presence of
asparaginyl endopeptidase-containing EVs derived from adenocarcinoma enhanced the
invasive ability of PDAC cells, whereas EVs lacking that molecule decreased their invasive
ability [100]. In the case of gastric cancer cells, the release of EVs with either high or low
CD97 has been described. These two types of EVs had differences on their promotion
of tumor invasion in Matrigel cultures in a dose-dependent manner. This supports the
protumoral effect of CD97 in this model [101].
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Some melanoma diseases overexpress RAB27A, a well-known protein in the mech-
anism of the formation of exosomes through the endocytic pathway. The silencing of
RAB27A in melanoma cell lines caused an inhibition of 3D spheroid invasion and cell
motility in vitro, as well as the spontaneous metastases in vivo. Interestingly, the effect can
be reverted by using RAB27A-replete EVs. However, the effect cannot be reverted if EVs
from melanoma RAB27A knockdown cells are used instead, suggesting that this gene is
the responsible of promoting a population of pro-invasive EVs [102]. A similar interplay
phenomenon can be observed using claudin-loaded EVs in claudin knockdown cells [103].
Remarkably, there is more evidence that tumoral cells are influenced by tumor-derived EVs.
A 3D co-culture performed with original colorectal adenocarcinoma cell line and cellular
subclones resistant to 5-fluorouracil demonstrated naïve spheroids release EVs loaded
with miR-200 family members. This miRNA family is well-known to repress EMT and
consequently, attenuate plasticity and migration. Horizontal miR-200 signaling prevented
resistant adenocarcinoma tumor spheroids to disrupt the continuous lymphendothelial
cell layer. In addition, they lost the ability to generate a circular chemorepellent-induced
defect [104]. On contrary, EVs from 5-fluorouracil resistant colorectal carcinoma, which are
devoid of miR200, accelerated circular chemorepellent-induced defects [105].
6.3. Effect of EVs Released by the Cellular Component of the Matrix over Tumor Cells
A common strategy to study the effect of EVs released by the cellular component
of the matrix is to generate organoids or spheroids using tumor cells. This could be also
translated into clinical approaches; for instance, the generation of organoids with patient-
derived colorectal cancer cells organoids. Fibroblast-derived EVs induce colony formation
of colorectal carcinoma organoids under hypoxia. In contrast, there is no major effect of
tumor-derived EVs on the activation of fibroblasts [60]. Fibroblast-derived EVs induce cell
proliferation (in an epidermal growth factor-dependent manner) to colorectal cancer patient-
derived organoids, and the data pointed to vesicular amphiregulin as a major factor in
inducing cell proliferation [106]. The EVs derived from macrophages had also an effect over
tumoral cells, and the effect increases when the release of EVs is induced by deoxycholic
acid treatment. EVs released in such condition increases the expression of spasmolytic
polypeptide-expressing metaplasia markers (TFF2 and GSII lectin) in gastric organoids
compared to EVs derived from macrophages without deoxycholic acid stimulation [107].
It has been also described that EVs secreted by MSCs obtained from patients with oral
leukoplakia and dysplasia, or oral carcinoma, exhibited induction of proliferation, migra-
tion and invasion of oral carcinoma cells in 3D coculture. This effect is significantly higher
than the one obtained co-culturing carcinoma cells and normal oral mucosa MSCs [108].
The homeostatic and antitumoral role of healthy MSC-derived EVs has been documented
in complex 3D cultures ultimately reverting CAFs back to endothelial cells [72]. However,
it has been also described that MSCs were capable to stimulate human glioblastoma cell
proliferation through a paracrine effect mediated by TGFB1. Moreover, MSCs in direct
cell-cell contact with glioblastoma cells provoked an increased proliferative and invasive
tumor cell behavior under 3D culture conditions [109].
7. Conclusions
In this review, we have described examples in which different 3D culture strategies are
employed to assess the effect of EVs over cells. The most common strategies are gel-based
cultures; both spheroid and organoids are used depending on the cell complexity. However,
there are also examples of microfluidic systems and bioreactors. These experiments showed
that cells in a 3D culture system behave differently than in 2D cultures, often in a more simi-
lar manner to in vivo conditions. This should be taken in account when performing studies
relative to drug sensitivity or EVs release. The possibility of implementing co-cultures
in 3D models allows complex interactions and obtaining results relative to the cellular
crosstalk, but we should also remark that such models require extensive characterization.
By using co-cultures, it can be described how tumoral EVs can modify cells from the
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matrix to display antitumoral activity, but also induce the release of EVs that feeds back
the activation of tumoral cells itself. In addition to the description of tumor biology, other
important application of 3D models focusses on the study of EVs as chemotherapy carriers.
The use of organoids and spheroids as models allows the measure of drug penetrance,
and the observed cell sensitivity to those drugs seems to be closer to in vivo results, when
compared to studies using cell monolayers. Another point where 3D cultures can help is to
solve the problems inherent to scale the production. Notably, bioreactors are of increasing
interest as a source of standardized and scalable production platforms of EVs. Although
there is still a long way to solve all the technical challenges, the adoption of 3D culture
models will bring a qualitative improvement on the discovery of potential applications of
EVs in cancer research.
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